Medicine Plus2025，Vol.2Issue(1)：P.1-7,7.DOI:10.1016/j.medp.2025.100073
Hypertrophic cardiomyopathy:current understanding and emerging therapeutics
Jia-Qi Dai 1Da Zhu 1Maurizio Taramasso 2Xiang-Bin Pan 3Dao-Wen Wang4
作者信息
- 1. Department of Structure Heart Center,Fuwai Yunnan Hospital,Chinese Academy of Medical Sciences,Affiliated Cardiovascular Hospital of Kunming Medical University,Kunming 650102,China
- 2. Heart Center Hirslanden Zurich,Zurich,999034,Switzerland
- 3. Department of Structure Heart Center,Fuwai Yunnan Hospital,Chinese Academy of Medical Sciences,Affiliated Cardiovascular Hospital of Kunming Medical University,Kunming 650102,China Department of Structural Heart Disease,National Center for Cardiovascular Disease,China and Fuwai Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037,China
- 4. Division of Cardiology,Department of Internal Medicine,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China Hubei Key Laboratory of Genetics and Molecular Mechanism of Cardiologic Disorders,Huazhong University of Science and Technology,Wuhan 430030,China
- 折叠
摘要
关键词
left ventricular hypertrophy/impaired cardiac functionmitral regurgitation/hypertrophic cardiomyopathy hcm/systolic anterior motion sam conditionwith/pathogenic mutations/sarcomeric proteins/hypertrophic cardiomyopathy/autosomal dominant分类
医药卫生引用本文复制引用
Jia-Qi Dai,Da Zhu,Maurizio Taramasso,Xiang-Bin Pan,Dao-Wen Wang..Hypertrophic cardiomyopathy:current understanding and emerging therapeutics[J].Medicine Plus,2025,2(1):P.1-7,7.基金项目
supported by the National Natural Science Foundation of China(82460073) （82460073）
the National Key Research and Development Program(2022YFC2503400) （2022YFC2503400）
the Major Science and Technology Special Plan Project of Yunnan Province(202302AA310045) （202302AA310045）
the Talent Trusteeship Program of Fuwai Yunnan Hospital(2024RCTJ-QN008). （2024RCTJ-QN008）
